Mesoblast Limited (MESO): Price and Financial Metrics
GET POWR RATINGS... FREE!
MESO POWR Grades
- MESO scores best on the Growth dimension, with a Growth rank ahead of 84.05% of US stocks.
- The strongest trend for MESO is in Stability, which has been heading up over the past 31 weeks.
- MESO ranks lowest in Quality; there it ranks in the 0th percentile.
MESO Stock Summary
- The capital turnover (annual revenue relative to shareholder's equity) for MESO is 0.01 -- better than only 8.79% of US stocks.
- With a price/sales ratio of 137.56, Mesoblast Ltd has a higher such ratio than 97.1% of stocks in our set.
- As for revenue growth, note that MESO's revenue has grown -80.84% over the past 12 months; that beats the revenue growth of just 2.43% of US companies in our set.
- If you're looking for stocks that are quantitatively similar to Mesoblast Ltd, a group of peers worth examining would be AUMN, ERYP, NAKD, CORR, and CPLG.
- MESO's SEC filings can be seen here. And to visit Mesoblast Ltd's official web site, go to www.mesoblast.com.
MESO Stock Price Chart Interactive Chart >
MESO Price/Volume Stats
|Current price||$8.53||52-week high||$21.28|
|Prev. close||$7.97||52-week low||$6.66|
|Day high||$8.53||Avg. volume||467,560|
|50-day MA||$7.76||Dividend yield||N/A|
|200-day MA||$11.17||Market Cap||1.11B|
Mesoblast Limited (MESO) Company Bio
Mesoblast Ltd. has established a diverse portfolio of product candidates based on its proprietary allogeneic, off-the-shelf mesenchymal lineage cell-based technology, with multiple active Phase 3 clinical programs. Mesoblast's lead product candidates target major diseases with significant unmet medical needs despite existing therapies. These include chronic heart failure, chronic low back pain due to degenerative disc disease, and immune-mediated conditions such as acute graft versus host disease and biologic refractory rheumatoid arthritis. The company is based in Melbourne, Australia.
MESO Latest News Stream
|Loading, please wait...|
MESO Latest Social Stream
View Full MESO Social Stream
Latest MESO News From Around the Web
Below are the latest news stories about Mesoblast Ltd that investors may wish to consider to help them evaluate MESO as an investment opportunity.
MESO earnings call for the period ending March 31, 2021.
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reported operational highlights and financial results for the period ended March 31, 2021. “We are pleased with the recent clinical outcomes regarding our lead product candidate remestemcel-L and continue to progress our regulatory discussions with the aim of achieving approval. Our focus and top priority remains on successfully bri
NEW YORK, June 02, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to discuss operational highlights and financial results for the period ending March 31, 2021. The webcast will begin at 6.30pm EDT, Wednesday, June 2; 8.30am AEST, Thursday, June 3, 2021. It can be accessed via: https://webcast.boardroom.media/mesoblast-limited/20210602/NaN60b6e20c3acee00019e165bd The archived we
Improved Outcomes in Inflammatory Lung Disease With Remestemcel-L Published in Respiratory Research Journal
NEW YORK, May 25, 2021 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the peer-reviewed journal Respiratory Research has published results showing that Mesoblast’s mesenchymal stromal cell (MSC) product candidate remestemcel-L significantly improved respiratory and functional clinical outcomes in patients with chronic obstructive pulmonary disease (COPD) and elevated levels of the inflammatory biomarker C-reactive protein (CRP). Patients with COPD and elevated CRP levels have increased rates of hospitalization and death.1 These results provide further rationale for potential use of remestemcel-L in inflammatory lung diseases, including COVID-19 acute respiratory distress syndrom...
Mesoblast Limited (MESO) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
MESO Price Returns